Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma
...rporated (Nasdaq: KOSN ) today announced that the tanespimycin in Myeloma Evaluation or TIME-1 pivotal Phase 3 trial for tanespimycin as a potential treatment for multiple myeloma is o...lment. TIME-1 is a pivotal Phase 3 trial comparing tanespimycin in combination with bortezomib (Velcade(R)) with b...Kosan Announces Data Presentations at ASCO 2008 Annual Meeting
...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
...alating Phase 1b clinical trial of Hsp90 inhibitor tanespimycin (KOS-953) in combination with bortezomib (Velcade(...n terms of convenience and ease of administration. tanespimycin is clearly an active and manageable agent and is d...ngful antitumor activity and tolerability with the tanespimycin plus bortezomib combination in multiple myeloma ac...Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
... tanespimycin is Industry's First Hsp90 Inhibitor to Enter Regis...IME Registration Program Utilizes New, Proprietary tanespimycin Formulation HAYWARD...olling patients. This marks the opening of Kosan's tanespimycin in Myeloma Evaluation or "TIME" registration progr...Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
... safety profile and Molecular of tanespimycin Therapeutics 13 (KOS-5: 953) -- ...lved in cancer cell growth and survival. Kosan's proprietary formulation of tanespimycin (KOS-953) is currently in Phase 1 and 2 clinical trials, primarily for mult...Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer
...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...Kosan Biosciences to Present at the Leerink Swann Solid Tumors Roundtable Conference
...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...Kosan Announces May 1, 2008 Conference Call and Webcast of First Quarter 2008 Financial Results
...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR
...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...Kosan Restructures Workforce to Focus Resources on Lead Clinical Programs
...porting advancement of its lead clinical programs, tanespimycin in multiple myeloma and in metastatic breast cance...hways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velc...ultiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic ...Kosan's Board of Directors Appoints Helen S. Kim as Chief Executive Officer
...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...Kosan Biosciences to Present at the Cowen and Company 28th Annual Health Care Conference
...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with bortezomib (Velcade(R)) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
...alue for the company in the near-term. -- The tanespimycin TIME registration program in multiple myeloma, ...myeloma in early 2009. -- Kosan plans to advance tanespimycin in metastatic breast cancer. To lay the groun...Kosan plans to commence enabling studies with tanespimycin as monotherapy and as combination therapy beg...Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
... top priorities in 2008 are the advancement of the tanespimycin TIME program in multiple myeloma and the tanespimycin metastatic breast cancer clinical program, and the...hways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with bort...